Last reviewed · How we verify
Diuretics : Furosemide
Diuretics : Furosemide is a Loop diuretic Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 3 development for Edema associated with congestive heart failure, Edema associated with hepatic cirrhosis, Edema associated with renal disease.
Furosemide inhibits sodium and chloride reabsorption in the thick ascending limb of the loop of Henle, promoting rapid urinary excretion of water and electrolytes.
Furosemide inhibits sodium and chloride reabsorption in the thick ascending limb of the loop of Henle, promoting rapid urinary excretion of water and electrolytes. Used for Edema associated with congestive heart failure, Edema associated with hepatic cirrhosis, Edema associated with renal disease.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Diuretics : Furosemide |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Loop diuretic |
| Target | Na-K-2Cl cotransporter (NKCC2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Furosemide is a loop diuretic that blocks the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, preventing reabsorption of sodium, potassium, and chloride. This osmotic effect reduces water reabsorption and increases urine output, leading to decreased blood volume and reduced fluid overload in tissues. It is one of the most potent diuretics available and is commonly used to manage edema and hypertension.
Approved indications
- Edema associated with congestive heart failure
- Edema associated with hepatic cirrhosis
- Edema associated with renal disease
- Hypertension
- Pulmonary edema
Common side effects
- Hypokalemia
- Hyperuricemia
- Ototoxicity (at high doses)
- Dehydration
- Hypotension
- Hyperglycemia
- Electrolyte imbalances
Key clinical trials
- Forebrain Electroneutral Transporters in Salt-sensitive Hypertension: an MRI Study (PHASE4)
- POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure (PHASE2, PHASE3)
- Empagliflozin in Acute Heart Failure (PHASE4)
- Comparison of the Effectiveness of Different Diuretic Therapies in the Management of Acute Heart Failure (NA)
- Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure (PHASE4)
- A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (PHASE3)
- Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure. (NA)
- "Effect of Albumin Combined With Furosemide in Critically Ill Patients With Fluid Overload: Impact on Urine Output and Renal Function" (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diuretics : Furosemide CI brief — competitive landscape report
- Diuretics : Furosemide updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Diuretics : Furosemide
What is Diuretics : Furosemide?
How does Diuretics : Furosemide work?
What is Diuretics : Furosemide used for?
Who makes Diuretics : Furosemide?
What drug class is Diuretics : Furosemide in?
What development phase is Diuretics : Furosemide in?
What are the side effects of Diuretics : Furosemide?
What does Diuretics : Furosemide target?
Related
- Drug class: All Loop diuretic drugs
- Target: All drugs targeting Na-K-2Cl cotransporter (NKCC2)
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Edema associated with congestive heart failure
- Indication: Drugs for Edema associated with hepatic cirrhosis
- Indication: Drugs for Edema associated with renal disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing